This is a repository copy of *Design and Engineering of Next Generation Mammalian Cell Factories*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/87999/

---

**Conference or Workshop Item:**

10.15445/01022014.24

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Design and Engineering of Next Generation Mammalian Cell Factories

David James
Department of Chemical and Biological Engineering, University of Sheffield

Abstract

Recombinant protein biopharmaceuticals are the top selling class of drugs, with global annual sales exceeding 100 billion USD. The majority of biopharmaceuticals are currently made in Chinese hamster ovary (CHO) cells, a transformed cell type originally isolated in the 1950’s. The adaptability and utility of CHO cell factories derives from our exploitation of their acquired genetic/functional variation using high-throughput functional screening and selection processes which enable industry to isolate and maintain cell factories with unusual and desirable properties. However, we still have a limited understanding of enabling cellular mechanisms that underpin the ideal manufacturing phenotype. This knowledge would permit design and construction of intrinsically better cell factories using the new concepts and tools of systems and synthetic biology. We now have the potential to provide disruptive new solutions for cell and process engineering, where we will be able to create bespoke cell factories with a predictable ability to manufacture a new generation of more complex biopharmaceutical proteins.